Akademska digitalna zbirka SLovenije - logo
E-resources
Peer reviewed Open access
  • Long-term RNAi knockdown of...
    Zharikov, Alevtina; Bai, Qing; De Miranda, Briana R.; Van Laar, Amber; Greenamyre, J. Timothy; Burton, Edward A.

    Neurobiology of disease, 05/2019, Volume: 125
    Journal Article

    α-Synuclein plays a central role in the pathogenesis of Parkinson's disease (PD); interventions that decrease its expression appear neuroprotective in PD models. Successful translation of these observations into effective therapies will be dependent on the safety of suppressing α-synuclein expression in the adult brain. We investigated long-term α-synuclein knockdown in the adult rat CNS. 8-month old animals received either AAV-shSnca (an RNA interference vector targeting the Snca mRNA transcript) or AAV-shCtrl (a control vector) unilaterally into the substantia nigra. No signs of systemic toxicity or motor dysfunction were observed in either experimental group over 12 months. Viral transgene expression persisted to 12 months post-inoculation, at which point Snca mRNA expression in substantia nigra dopaminergic neurons of animals that received AAV-shSnca was decreased by ≈90%, and α-synuclein immunoreactivity by >70% relative to the control side. Stereological quantification of Nissl-labeled neurons showed no evidence of neurodegeneration in the substantia nigra 12 months after inoculation with either vector, and we observed abundant dopaminergic neurons with minimal α-synuclein immunoreactivity that appeared otherwise unremarkable in the AAV-shSnca group. Despite the absence of neurodegeneration, some loss of TH expression was evident in nigral neurons after transduction with either vector, presumably a non-specific consequence of vector delivery, cellular transduction, or expression of shRNA or GFP. We conclude that long-term α-synuclein knockdown in the substantia nigra does not cause significant functional deficits in the ascending dopaminergic projection, or neurodegeneration. These findings are encouraging that it may be feasible to target α-synuclein expression therapeutically in PD. •shRNA targeting Snca was delivered to nigral dopamine neurons using an AAV vector.•Snca mRNA was reduced by 90% and α-synuclein expression by >70% at 12 months.•No motor deficit or neuronal loss was observed after α-synuclein knockdown.•Long-term α-synuclein knockdown in the adult brain does not cause neurodegeneration.